# Viridian Therapeutics **Source:** https://geo.sig.ai/brands/viridian-therapeutics **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** viridiantherapeutics.com **Last Updated:** 2026-04-14 ## Summary Greenwood Village CO YC W20 clinical biotech (NASDAQ: VRDN) with $636.6M cash; veligrotug BLA submission H2 2025 for thyroid eye disease competing with Tepezza; FcRn inhibitor platform with VRDN-003 and VRDN-006 in development. ## Company Overview Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment. Viridian's FcRn inhibitor platform addresses the treatment gap in thyroid eye disease and IgG-mediated autoimmune conditions: thyroid eye disease (affecting 50,000+ new US patients annually, associated with Graves' hyperthyroidism) causes the immune system to produce IgG antibodies that attack the thyroid-stimulating hormone receptor in orbital tissue — causing proptosis (eye protrusion), diplopia (double vision), and orbital inflammation that significantly impairs quality of life. FcRn inhibitors (blocking the neonatal Fc receptor that recycles IgG antibodies, thereby reducing circulating IgG levels and the autoantibody burden driving the disease) represent a mechanistically differentiated approach from the currently approved standard (teprotumumab/Tepezza, which targets IGF-1R). Viridian's subcutaneous formulation (self-injectable) versus teprotumumab's IV infusion provides meaningful patient convenience differentiation if clinical efficacy is comparable. In 2025, Viridian competes in the thyroid eye disease therapeutics and rare autoimmune market with Amgen/Horizon Therapeutics (NASDAQ: AMGN, Tepezza for TED, $1.9B 2023 revenue), Immunovant (NASDAQ: IMVT, FcRn inhibitor platform, $400M raised), and Argenx (NASDAQ: ARGX, efgartigimod FcRn inhibitor, $1.7B revenue) for TED and IgG-autoantibody disease FcRn inhibitor therapy market positioning. The NASDAQ listing and $636.6M cash position reflect biotech market financing strength. Y Combinator W20 backing (unusual for a clinical-stage biotech) provides organizational credibility and investor network connectivity. The 2025 strategy focuses on the veligrotug BLA submission and FDA review process, enrolling the VRDN-003 Phase 3 program, and positioning Viridian as a multi-asset rare autoimmune company beyond TED with the FcRn platform. ## Frequently Asked Questions ### What is Viridian Therapeutics? Viridian Therapeutics is a clinical-stage biotechnology company developing innovative medicines for serious and rare diseases. The publicly traded company (NASDAQ: VRDN) focuses on thyroid eye disease (TED) and other rare conditions, with its lead candidate veligrotug currently in development. ### What products and services does Viridian Therapeutics offer? Viridian is developing three main drug candidates: veligrotug for thyroid eye disease (TED) treatment, VRDN-003 for rare diseases, and VRDN-006 for IgG reduction. The company specializes in rare disease drug development with these clinical-stage therapies. ### Who are Viridian Therapeutics' target customers? Viridian Therapeutics develops treatments for patients suffering from thyroid eye disease (TED) and other serious rare diseases. Their therapies are designed for individuals with these specific medical conditions who require specialized treatment options. ### When was Viridian Therapeutics founded? Viridian Therapeutics was founded in 2015. The company later participated in Y Combinator's Winter 2020 (W20) batch. ### Where is Viridian Therapeutics located? Viridian Therapeutics is based in Boulder, Colorado. ### What is Viridian Therapeutics' financial position? As of March 2025, Viridian maintains $636.6M in cash and short-term investments, sufficient to fund operations into the second half of 2027. The company is publicly traded on NASDAQ under the ticker symbol VRDN and was backed by Y Combinator (W20). ### What are Viridian Therapeutics' key achievements? Viridian has achieved positive Phase 3 clinical trial data for veligrotug in thyroid eye disease (TED) treatment. The company maintains a strong cash position of $636.6M as of March 2025 and is advancing multiple clinical-stage drug candidates toward regulatory submissions. ### What is Viridian Therapeutics' approach to drug development? Viridian focuses on developing innovative medicines for serious and rare diseases through clinical-stage biotechnology research. The company invested $86.6M in R&D expenses in Q2 2025, reflecting accelerated clinical development across its pipeline. ### How can I learn more about Viridian Therapeutics? Viridian Therapeutics is a publicly traded company on NASDAQ under the ticker symbol VRDN. The company is based in Boulder, Colorado and provides updates on its clinical development programs through public filings and announcements. ### What are Viridian Therapeutics' recent developments? Viridian plans to submit a BLA (Biologics License Application) for veligrotug in H2 2025 and an MAA to the EMA in H1 2026. The company expects VRDN-003 topline data in H1 2026 and VRDN-006 proof-of-concept data in Q3 2025. ## Tags healthtech, north-america, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*